Please enable Javascript
Keightley Amen
Articles by Keightley Amen
Adding Parsaclisib to Ruxolitinib Improves Myelofibrosis Symptoms, Spleen Volume
Keightley Amen
Myelofibrosis
|
February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Read More
Spleen Volume Reduction Predicts OS in Myelofibrosis Treated with Pacritinib
Keightley Amen
Myelofibrosis
|
February 8, 2024
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Read More
Patients with CLL or SLL Who Receive Ibrutinib Versus Chemoimmunotherapy Are Less Likely to Require Second-Line Treatment
Keightley Amen
Chronic Lymphocytic Leukemia
|
September 5, 2023
The results provide evidence of the real-world effectiveness of ibrutinib in an insured U.S. population.
Read More
Phase III Trial Investigates Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL
Keightley Amen
Meeting News
|
September 5, 2023
A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Study Explores Add-On Treatment CK0804 in Patients with Myelofibrosis
Keightley Amen
Myelofibrosis
|
September 5, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Read More
Study Supports Use of Pelabresib Monotherapy in High-Risk Essential Thrombocythemia
Keightley Amen
Myeloproliferative Neoplasms
|
February 8, 2024
The phase II MANIFEST study suggested that pelabresib could be beneficial in myelofibrosis.
Read More
Study Works to Establish Dose and Safety of BET Inhibitor INCB057643 in Advanced Myeloid Neoplasms
Keightley Amen
Myelofibrosis
|
September 5, 2023
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
Read More
Agent Orange Exposure Associated with MPNs in Veterans
Keightley Amen
Myeloproliferative Neoplasms
|
February 8, 2024
The case-control study used information from the Veterans Affairs Informatics and Computing Infrastructure database.
Read More
Study Supports Safety, Efficacy of Luspatercept for Anemia in Myelofibrosis
Keightley Amen
Myelofibrosis
|
September 5, 2023
Researchers followed the patients for three years after their final dose of luspatercept.
Read More
Jaktinib Reduces Spleen Volume, Symptoms in Patients with Myelofibrosis Who Failed Ruxolitinib
Keightley Amen
Myelofibrosis
|
September 5, 2023
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Read More
Study Finds Selinexor Plus Ruxolitinib Has Promise in Myelofibrosis
Keightley Amen
Myelofibrosis
|
September 5, 2023
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
Read More
Preliminary Data Show Potential Effectiveness of Lisaftoclax Against Waldenström Macroglobulinemia
Keightley Amen
Indolent B-Cell Lymphoma
|
September 5, 2023
Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects.
Read More
ZUMA-2 Real-World Data Show Improved Survival in MCL
Keightley Amen
Mantle Cell Lymphoma
|
September 5, 2023
These findings suggest that real-world outcomes of brexu-cel are consistent regardless of prior BTK inhibition, brexu-cel.
Read More
Study Explores Combo of Lenalidomide or Ibrutinib Plus R-MPV in Newly Diagnosed PCNSL
Keightley Amen
Aggressive B-Cell Lymphoma
|
September 5, 2023
Targeted induction immunochemotherapy with ibrutinib or lenalidomide and R-MPV is feasible, according to the researchers.
Read More
Patients with MPNs at Higher Risk for Hospital Readmission After Afib
Keightley Amen
Myeloproliferative Neoplasms
|
September 5, 2023
In patients with Afib, MPNs are linked to an increased risk of hospital readmissions for bleeding and arterial thrombosis.
Read More
Research Reveals Distinct Risk Factors for Arterial and Venous Thrombotic Events in MPN
Keightley Amen
Myeloproliferative Neoplasms
|
December 12, 2022
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Read More
Study Explores Rare Myeloid Neoplasms with NPM1 Mutations
Keightley Amen
Meeting News
|
December 11, 2022
A recent study evaluated patients with rare myeloid neoplasms who had NPM1 mutations.
Read More
Study Supports Usefulness of IPSS-M in Hypoplastic MDS
Keightley Amen
Meeting News
|
December 11, 2022
The IPSS-M Risk Stratification Model led to reclassification of almost half of patients with hypoplastic MDS.
Read More
Research Suggests ‘Clone Size by Conventional Cytogenetics’ Can Predict Outcomes in MDS
Keightley Amen
Myelodysplastic Syndromes
|
December 11, 2022
The number of cells with chromosomal abnormalities was significantly associated with clinical features and outcomes in MDS.
Read More
Study Explores First-in-Class CXCR1/2 Inhibitor SX-682 After HMA Failure in MDS
Keightley Amen
Meeting News
|
December 11, 2022
SX-682 was effective and well tolerated at a dose of 200 mg twice daily in patients with MDS.
Read More
Load More